| abstract |
The present invention relates to the use of PM01183 and several anticancer drugs, in particular antitumor platinum coordination complexes, antimetabolites, mitotic inhibitors, anticancer antibiotics, topoisomerase I and / or II inhibitors, proteasome inhibitors, histone deacetylase inhibitors, nitrogen Combinations with anticancer drugs selected from mustard alkylating agents, nitrosourea alkylating agents, non-classical alkylating agents, estrogen antagonists, androgen antagonists, mTOR inhibitors, tyrosine kinase inhibitors and other drugs selected from aprolidine, ET-743, PM02734 and PM00104 And combinations of these in cancer therapy. |